For type 1 or type 2 diabetes. Sold as Symlin. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Pramlintide Acetate (sold as Symlin), first approved Mar 16, 2005, with 1 new use approved and 0 published complete response letters.
| Symlinpen 120 | Part D | $1.0M | -49% | 116 |
| Symlinpen 60 | Part D | $838K | -41% | 172 |
| Outpatient Pramlintide StudyType 1 Diabetes · Oregon Health and Science University | Not applicable | Not yet recruiting | Nov 3, 2026 |
| Postprandial Regulation of Bone Perfusion in Healthy IndividualsHealthy Adult Participants, Bone Physiology · University of Copenhagen | Not applicable | Not yet recruiting | Jul 1, 2026 |
| Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy HumansObesity & Overweight · University Hospital, Gentofte, Copenhagen | Not applicable | Recruiting | Apr 1, 2026 |
| Amylin-Induced Migraine Attacks Without AuraHeadache Disorders, Primary, Headache Disorders · Danish Headache Center | Not applicable | Not yet recruiting | Jan 14, 2026 |
| Hypersensitivity to Amylin in Post-Traumatic HeadacheHeadache Disorders, Secondary, Brain Diseases · Danish Headache Center | Not applicable | Not yet recruiting | Jan 14, 2026 |
| Multi-Center Development of a Novel Diagnostic Test for Alzheimer's DiseaseAlzheimer Disease, Mild Cognitive Impairment · Boston University | Early phase 1 | Active, not recruiting | Jun 19, 2018 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Mar 16, 2005 | SymlinNDA 21332 · New molecular entity | Astrazeneca AB | 10 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Astrazeneca AB